Ocrelizumab shows effectiveness in Multiple Sclerosis
Ocrelizumab shows effectiveness in Multiple Sclerosis
Roche Holding AG said Thursday that a phase II showed its experimental drug ocrelizumab maintained significant reduction in disease activity for multiple sclerosis patients for almost two years. Roche said phase III trials underway to investigate ocrelizumab in two forms of MS
96-week results from a phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common clinical form of the disease. The study showed that the significant reduction in disease activity as measured by the total number of active brain lesions and relapses previously reported for 24 weeks, was maintained through 96 weeks.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1768 Views
-
Last post by frodo
-
- 1 Replies
- 1827 Views
-
Last post by frodo
-
- 0 Replies
- 1562 Views
-
Last post by frodo
-
- 0 Replies
- 1623 Views
-
Last post by frodo
-
- 0 Replies
- 3621 Views
-
Last post by frodo
-
- 0 Replies
- 1867 Views
-
Last post by NHE
-
- 0 Replies
- 2211 Views
-
Last post by frodo
-
- 0 Replies
- 1248 Views
-
Last post by frodo
-
- 0 Replies
- 1661 Views
-
Last post by frodo